Chemotherapy and Novel Treatment Combinations in Breast Cancer
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 14064
Special Issue Editor
Interests: breast cancer; gynecologic cancer; genetic counseling; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite the many improvements in its diagnosis and treatment, breast cancer remains a major public health issue for most countries, particularly in the Western world. The development of new treatment combinations and the introduction of new families of active agents, together with the potential identification of more homogeneous subgroups of patients based on precision medicine data, has created a novel research area attracting the interest of both scientists and patients, in the pursuit of more effective treatments and a better understanding of the disease itself. We are pleased to invite submissions focusing on current trends in the treatment of all stages of breast cancer, including chemotherapy and novel agents.We welcome manuscripts in the following formats:·
- Original research;
- Basic research;
- Translational and clinical research; ·
- Review articles; ·
- Short communications; ·
- Case reports;
We are looking forward to your contributions.
Dr. Eleni Timotheadou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- adjuvant
- neoadjuvant
- advanced
- HER2-positive
- triple-negative
- BRCA-mutations
- CDK4/6 inhibitors
- endocrine therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
